Other

Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows

Royalty Pharma Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows decreased by 21.0% to $2.52B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 26.8%, from $3.44B to $2.52B. Over 5 years (FY 2020 to FY 2025), Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows shows an upward trend with a 27.6% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ2 2020
Last reportedQ1 2026
Metric ID: other_financing_receivable_allowance_for_credit_loss_cha_8133a3

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$931.65M$1.13B$1.38B$1.62B$1.74B$2.09B$2.48B$2.50B$2.75B$2.99B$2.93B$3.51B$3.69B$3.42B$3.55B$3.44B$3.24B$3.25B$3.19B$2.52B
QoQ Change—+21.1%+22.7%+16.9%+7.4%+20.4%+18.4%+1.0%+9.9%+9.0%-2.3%+20.0%+5.2%-7.3%+3.7%-3.2%-5.7%+0.3%-2.0%-21.0%
YoY Change————+86.5%+85.5%+78.9%+54.5%+58.1%+43.1%+18.2%+40.4%+34.4%+14.3%+21.3%-2.1%-12.2%-5.1%-10.3%-26.8%
Range$931.65M – $3.69B
CAGR+23.3%
Avg YoY Growth+29.9%
Median YoY Growth+27.9%
Current Streak2 quarters decline

Frequently Asked Questions

What is Royalty Pharma's financing receivable, allowance for credit loss, changes in expected cash flows?
Royalty Pharma (RPRX) reported financing receivable, allowance for credit loss, changes in expected cash flows of $2.52B in Q1 2026.
How has Royalty Pharma's financing receivable, allowance for credit loss, changes in expected cash flows changed year-over-year?
Royalty Pharma's financing receivable, allowance for credit loss, changes in expected cash flows decreased by 26.8% year-over-year, from $3.44B to $2.52B.
What is the long-term trend for Royalty Pharma's financing receivable, allowance for credit loss, changes in expected cash flows?
Over 5 years (2020 to 2025), Royalty Pharma's financing receivable, allowance for credit loss, changes in expected cash flows has grown at a 27.6% compound annual growth rate (CAGR), from $940.11M to $3.19B.